Mita, M., Fu, S., Piha-Paul, S. A., Janku, F., Mita, A., Natale, R., . . . Naing, A. (2017). Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs.
Citación estilo ChicagoMita, Monica, et al. "Phase I Trial of MEK 1/2 Inhibitor Pimasertib Combined With MTOR Inhibitor Temsirolimus in Patients With Advanced Solid Tumors." Invest New Drugs 2017.
Cita MLAMita, Monica, et al. "Phase I Trial of MEK 1/2 Inhibitor Pimasertib Combined With MTOR Inhibitor Temsirolimus in Patients With Advanced Solid Tumors." Invest New Drugs 2017.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.